Heleen H. Van Acker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Heleen H. Van Acker has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Evelien Smits
Center for Oncological Research, University of Antwerp, 2610 Antwerp, Belgium
6 shared publications Sébastien Anguille
Division of Hematology, Antwerp University Hospital, Edegem, Belgium
5 shared publicationsViggo F. Van Tendeloo
Laboratory of Experimental Hematology, Tumor Immunology Group (TIGR), Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium
4 shared publications- Eva Lion
Laboratory of Experimental Hematology, Vaccine & Infectious Disease institute (VAXINFECTIO), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
3 shared publications - Viggo F. I. Van Tendeloo
University of Antwerp
3 shared publications Yannick Willemen
Laboratory of Experimental Hematology, Tumor Immunology Group (TIGR), Vaccine and Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Faculty of Medicine and Health Sciences, Antwerp, Belgium
3 shared publications
Latest Publications
- 1 June 2018
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 41, 54-64
The role of the common gamma-chain family cytokines in γδ T cell-based anti-cancer immunotherapy
- 1 June 2018
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 41, 54-64
The role of the common gamma-chain family cytokines in γδ T cell-based anti-cancer immunotherapy
- Open Access
- 10 April 2018
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 658
Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion
Dendritic cell (DC) vaccination can be an effective post-remission therapy for acute myeloid leukemia (AML). Yet, current DC vaccines do not encompass the ideal stimulatory triggers for innate gamma delta (γδ) T cell anti-tumor activity. Promoting type 1 cytotoxic γδ T cells in patients with AML is, however, most interesting, considering these unconventional T cells are primed for rapid function and exert meaningful control over AML. In this work, we demonstrate that interleukin (IL)-15 DCs have the capacity to enhance the anti-tumoral functions of γδ T cells. IL-15 DCs of healthy donors and of AML patients in remission induce the upregulation of cytotoxicity-associated and co-stimulatory molecules on the γδ T cell surface, but not of co-inhibitory molecules, incite γδ T cell proliferation and stimulate their interferon-γ production in the presence of blood cancer cells and phosphoantigens. Moreover, the innate cytotoxic capacity of γδ T cells is significantly enhanced upon interaction with IL-15 DCs, both towards leukemic cell lines and allogeneic primary AML blasts. Finally, we address soluble IL-15 secreted by IL-15 DCs as the main mechanism behind the IL-15 DC-mediated γδ T cell activation. These results indicate that the application of IL-15-secreting DC subsets could render DC-based anti-cancer vaccines more effective through, among others, the involvement of γδ T cells in the anti-leukemic immune response.
- 10 April 2018
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 9, 658
Open AccessInterleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion
Dendritic cell (DC) vaccination can be an effective post-remission therapy for acute myeloid leukemia (AML). Yet, current DC vaccines do not encompass the ideal stimulatory triggers for innate gamma delta (γδ) T cell anti-tumor activity. Promoting type 1 cytotoxic γδ T cells in patients with AML is, however, most interesting, considering these unconventional T cells are primed for rapid function and exert meaningful control over AML. In this work, we demonstrate that interleukin (IL)-15 DCs have the capacity to enhance the anti-tumoral functions of γδ T cells. IL-15 DCs of healthy donors and of AML patients in remission induce the upregulation of cytotoxicity-associated and co-stimulatory molecules on the γδ T cell surface, but not of co-inhibitory molecules, incite γδ T cell proliferation and stimulate their interferon-γ production in the presence of blood cancer cells and phosphoantigens. Moreover, the innate cytotoxic capacity of γδ T cells is significantly enhanced upon interaction with IL-15 DCs, both towards leukemic cell lines and allogeneic primary AML blasts. Finally, we address soluble IL-15 secreted by IL-15 DCs as the main mechanism behind the IL-15 DC-mediated γδ T cell activation. These results indicate that the application of IL-15-secreting DC subsets could render DC-based anti-cancer vaccines more effective through, among others, the involvement of γδ T cells in the anti-leukemic immune response.
- Open Access
- 24 July 2017
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 8, 892
CD56 in the Immune System: More Than a Marker for Cytotoxicity?
Over the past years, the phenotypic and functional boundaries distinguishing the main cell subsets of the immune system have become increasingly blurred. In this respect, CD56 (also known as NCAM) is a very good example. CD56 is the archetypal phenotypic marker of natural killers cells, but can actually be expressed by many more immune cells, including alpha beta (αβ) T cells, gamma delta (γδ) T cells, dendritic cells and monocytes. Common to all these CD56-expressing cell types are strong immunostimulatory effector functions, including T helper 1 cytokine production and an efficient cytotoxic capacity. Interestingly, both numerical and functional deficiencies and phenotypic alterations of the CD56+ immune cell fraction have been reported in patients with various infectious, autoimmune or malignant diseases. In this review, we will discuss our current knowledge on the expression and function of CD56 in the hematopoietic system, both in health and disease.
- 24 July 2017
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 8, 892
Open AccessCD56 in the Immune System: More Than a Marker for Cytotoxicity?
Over the past years, the phenotypic and functional boundaries distinguishing the main cell subsets of the immune system have become increasingly blurred. In this respect, CD56 (also known as NCAM) is a very good example. CD56 is the archetypal phenotypic marker of natural killers cells, but can actually be expressed by many more immune cells, including alpha beta (αβ) T cells, gamma delta (γδ) T cells, dendritic cells and monocytes. Common to all these CD56-expressing cell types are strong immunostimulatory effector functions, including T helper 1 cytokine production and an efficient cytotoxic capacity. Interestingly, both numerical and functional deficiencies and phenotypic alterations of the CD56+ immune cell fraction have been reported in patients with various infectious, autoimmune or malignant diseases. In this review, we will discuss our current knowledge on the expression and function of CD56 in the hematopoietic system, both in health and disease.
- Open Access
- 13 January 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (8) , 13652-13665
Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells
Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells
- 13 January 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (8) , 13652-13665
Open AccessDesirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells
Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells
- Open Access
- 29 September 2016
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 9 (1) , 1-13
Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells
Adoptive immunotherapy is gaining momentum to fight malignancies, whereby γδ T cells have received recent attention as an alternative cell source as to natural killer cells and αβ T cells. The advent of γδ T cells is largely due to their ability to recognize and target tumor cells using both innate characteristic and T cell receptor (TCR)-mediated mechanisms, their capacity to enhance the generation of antigen-specific T cell responses, and their potential to be used in an autologous or allogeneic setting. In this study, we explored the beneficial effect of the immunostimulatory cytokine interleukin (IL)-15 on purified γδ T cells and its use as a stimulatory signal in the ex vivo expansion of γδ T cells for adoptive transfer. The expansion protocol was validated both with immune cells of healthy individuals and acute myeloid leukemia patients. We report that the addition of IL-15 to γδ T cell cultures results in a more activated phenotype, a higher proliferative capacity, a more pronounced T helper 1 polarization, and an increased cytotoxic capacity of γδ T cells. Moreover γδ T cell expansion starting with peripheral blood mononuclear cells from healthy individuals and acute myeloid leukemia patients is boosted in the presence of IL-15, whereby the antitumor properties of the γδ T cells are strengthened as well. Our results support the rationale to explore the use of IL-15 in clinical adoptive therapy protocols exploiting γδ T cells.
- 29 September 2016
- Published by Springer Nature in Journal of Hematology & Oncology
- Vol. 9 (1) , 1-13
Open AccessInterleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells
Adoptive immunotherapy is gaining momentum to fight malignancies, whereby γδ T cells have received recent attention as an alternative cell source as to natural killer cells and αβ T cells. The advent of γδ T cells is largely due to their ability to recognize and target tumor cells using both innate characteristic and T cell receptor (TCR)-mediated mechanisms, their capacity to enhance the generation of antigen-specific T cell responses, and their potential to be used in an autologous or allogeneic setting. In this study, we explored the beneficial effect of the immunostimulatory cytokine interleukin (IL)-15 on purified γδ T cells and its use as a stimulatory signal in the ex vivo expansion of γδ T cells for adoptive transfer. The expansion protocol was validated both with immune cells of healthy individuals and acute myeloid leukemia patients. We report that the addition of IL-15 to γδ T cell cultures results in a more activated phenotype, a higher proliferative capacity, a more pronounced T helper 1 polarization, and an increased cytotoxic capacity of γδ T cells. Moreover γδ T cell expansion starting with peripheral blood mononuclear cells from healthy individuals and acute myeloid leukemia patients is boosted in the presence of IL-15, whereby the antitumor properties of the γδ T cells are strengthened as well. Our results support the rationale to explore the use of IL-15 in clinical adoptive therapy protocols exploiting γδ T cells.
- 1 February 2016
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 158, 24-40
Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials
- 1 February 2016
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 158, 24-40
Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials
- Open Access
- 2 April 2015
- Published by Taylor & Francis in OncoImmunology
- Vol. 4 (8) , e1021538
Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy
Gamma delta (γδ) T cells are the all-rounders of our immune-system with their major histocompatibility complex-unrestricted cytotoxicity, capacity to secrete immunosti-mulatory cytokines and ability to promote the generation of tumor antigen-specific CD8+ and CD4+ T cell responses. Dendritic cell (DC)-based vaccine therapy has the prospective to harness these unique features of the γδ T cells in the fight against cancer. In this review, we will discuss our current knowledge on DC-mediated γδ T cell activation and related opportunities for tumor immunologists.
- 2 April 2015
- Published by Taylor & Francis in OncoImmunology
- Vol. 4 (8) , e1021538
Open AccessEmpowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy
Gamma delta (γδ) T cells are the all-rounders of our immune-system with their major histocompatibility complex-unrestricted cytotoxicity, capacity to secrete immunosti-mulatory cytokines and ability to promote the generation of tumor antigen-specific CD8+ and CD4+ T cell responses. Dendritic cell (DC)-based vaccine therapy has the prospective to harness these unique features of the γδ T cells in the fight against cancer. In this review, we will discuss our current knowledge on DC-mediated γδ T cell activation and related opportunities for tumor immunologists.